DITEST
Phase 1Small molecule
DITEST is one of 35 small molecule programs targeting Hypogonadism. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
48 competitors in Hypogonadism
#DrugCompanyPhaseTrials
1Estrace
Novo NordiskApproved
Victoza
Novo NordiskApproved
Andriol
AAuxilium
Approved
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Approved
Delatestryl
AAntares Pharma Inc.
Approved
Arimidex
IIstituto Clinico Humanitas
Approved
Trelstar
OOncoVerity, Inc.
Approved
Depo-Testosterone
AAzurity Pharmaceuticals
Approved
Clomid
EMD SeronoApproved
Avodart
Akero TherapeuticsApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DITEST. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- NNeurocrine UK Limited